Recombinant TNF alpha (Infliximab Biosimilar) antibody
Reactivity: Human
FACS, in vivo
Host: Mouse
Monoclonal
cA2
unconjugated
Recombinant Antibody
-
- Target See all TNF alpha (Infliximab Biosimilar) products
- TNF alpha (Infliximab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This TNF alpha (Infliximab Biosimilar) antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- Purpose
- Infliximab Biosimilar, TNF alpha Monoclonal Antibody
- Specificity
- The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.
- Characteristics
- Recombinant Chimeric IgG1 Monoclonal Antibody.
- Purification
- Protein A affinity column
- Purity
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
- < 1 EU per 1 mg of the protein by the LAL method.
- Immunogen
- The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.
- Clone
- CA2
- Isotype
- IgG1 kappa
-
anti-TNF alpha (Infliximab Biosimilar) antibody
Reactivity: Human FACS, in vivo, ELISA Host: Human Monoclonal cA2 unconjugated Recombinant Antibody
-
- Application Notes
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 mg/mL
- Buffer
- PBS, pH 7.4, no stabilizers or preservatives.
- Preservative
- Without preservative
- Handling Advice
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- Expiry Date
- 12 months
-
- Target
- TNF alpha (Infliximab Biosimilar)
- Abstract
- TNF alpha (Infliximab Biosimilar) Products
- Synonyms
- DIF antibody, TNF-alpha antibody, TNFA antibody, TNFSF2 antibody, tumor necrosis factor antibody, TNF antibody
- Target Type
- Biosimilar
- Background
-
Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.
Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.
-
You are here:
